Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:8 Number:26 ISSN#:2563-5476
Author Verified
Meta-analysis
ACE Report #4431
Ace Report Cover General Orthopaedics

Dabigatran: potential higher risk of acute coronary event compared to other anticoagulants


How to Cite

OrthoEvidence. Dabigatran: potential higher risk of acute coronary event compared to other anticoagulants. ACE Report. 2013;2(8):26. Available from: https://myorthoevidene.com/AceReport/Report/4431

Study Type:Meta-analysis/Systematic Review
OE Level Evidence:2
Journal Level of Evidence:N/A

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

Arch Intern Med. 2012 Mar 12;172(5):397-402. doi: 10.1001/archinternmed.2011.1666. Epub 2012 Jan 9

Contributing Authors: K Uchino AV Hernandez

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

In this meta-analysis, 7 studies (30,514 participants with atrial fibrillation (AF)) reporting the risk of developing myocardial infarction (MI) or acute coronary syndrome (ACS) from the use of dabigatran etexilate were evaluated. In comparison to warfarin, enoxaparin, or placebo, results indicated that dabigatran was associated with an increased risk of myocardial infarction (MI) and acute corona...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.